|View printer-friendly version|
|Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting|
In the poster, titled “Strategies for Selection of AAV Vectors for Administration to Liver: Studies in Nonhuman Primates” (Abstract # 2316), researchers at the
“We are pleased to announce key findings from our highly productive collaboration with
For more information, please visit www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding development, preclinical results, and the continued progress of Dimension’s portfolio and program. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Dimension’s product candidates, including its lead candidate, DTX101, will not successfully be developed or commercialized; and the risks described under the caption "Risk Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended